Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sequenom, Inc. (SQNM) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (106)	6/18/2002 11:04:01 AM
From: tuck	Read Replies (1) \| Respond to of 364

>>SAN DIEGO, June 18 /PRNewswire-FirstCall/ -- SEQUENOM, Inc. (Nasdaq: SQNM - News), a discovery genetics company, today announced a joint research agreement with Samsung Advanced Institute of Technology (SAIT) in Korea. The agreement represents SAIT's first significant venture in DNA technology and analysis. The collaboration will include genome-wide screens to identify potential disease-related markers. SAIT plans to use the markers for the development of their biochips. SAIT has already installed multiple MassARRAY(TM) systems, SEQUENOM's high performance genotyping platform. SEQUENOM and SAIT will share commercial rights to disease gene discoveries and other intellectual property generated under the research collaboration. "SAIT is committed to pursuing developments in state-of-the-art technology, and the fusion of information technology and biotechnology will create new business opportunities," said Wook Sun, President and CEO at SAIT. "We looked at the companies and technologies in the industry and determined that SEQUENOM clearly possessed the strongest technology and most intelligent strategies. Our collaboration with SEQUENOM supports our overall strategy and provides us with a fundamental competitive advantage moving forward." "SAIT is an established leader in cutting-edge technology and we are proud to collaborate on their initiative in DNA technology and analysis," said Toni Schuh, Ph.D., SEQUENOM's President and Chief Executive Officer. "Our relationship with SAIT is a strategic fit for SEQUENOM, serving both our genetic systems and pharmaceutical business units. SAIT has well established infrastructure and core competency to ensure the success of our research collaboration." About SAIT Samsung Advanced Institute of Technology is Samsung's Central R&D Center committed to researching technologies aimed at the 21st century. To fulfill this commitment, SAIT is now researching frontier technologies in the areas of information technology, nanotechnology and bioelectronics, such as biochips, all of which will contribute to the well being of the global community in this millennium. To learn more about SAIT, visit its website at sait.samsung.co.kr .<<